EUVIMEDEUVIMED entdecken
Crossref

Engineered Nonhormonal, Cationic Proinsulin Variants Prolong Lymphatic Drainage

Grant M Downes iD, Amber S Griffith, Kyle D Apley iD, Mark J Miller, Peggy L Kendall, Cory J Berkland iD

Molecular Pharmaceutics · 2025

DOI: 10.1021/acs.molpharmaceut.5c01189 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Grant M Downes und 5 weiteren Autor:innen. Beteiligte Einrichtung: Bioengineering Graduate Program, University of Kansas, Lawrence, Kansas 66045 United States. Hauptthemen laut MEDLINE: Proinsulin. Die Arbeit nennt 52 Literaturangaben. Gefördert von: University of Kansas.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Type 1 diabetes patients develop autoantibodies against pancreatic-islet-derived autoantigens, with proinsulin emerging as an early and dominant target. Existing antigen-specific immunotherapy (ASIT) strategies remain limited by poor antigen stability and rapid clearance, leading to reliance on global immunosuppression. To address these challenges, we engineered nonhormonal variants of proinsulin featuring cationic peptide "tails" at the C-terminus. All the expressed cationic proinsulin variants retained low-nM binding affinity to mouse anti-insulin mAb125 and exhibited low affinity for the insulin receptor. In addition, all variants exhibited physical stability profiles similar to those of proinsulin. A diffusion assay was performed in a viscous hyaluronic acid gel to simulate subcutaneous injection. The addition of a cationic binding motif to proinsulin slowed diffusion compared to that of unmodified proinsulin. Modifying autoantigens such as proinsulin with cationic "tails", therefore, slows release, providing a depot-like effect with prolonged antigen presence at the injection site. This slow-release strategy also provided a steady accumulation of proinsulin in the draining lymph nodes. This strategy may enhance the efficacy of ASITs by negating insulin receptor activity, promoting autoimmune cell engagement, and sustaining exposure to draining lymph nodes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProinsulinAnimalsMiceHumansImmunotherapyCationsDiabetes Mellitus, Type 1Lymph NodesAutoantigensInsulinReceptor, InsulinFemale

Stichwörter der Autor:innen

antigen-specific immunotherapycationic proinsulinlymphatic transportslow antigen releasesubcutaneous injectiontype 1 diabetes

Substanzen

ProinsulinCationsAutoantigensInsulinReceptor, Insulin

Autor:innen und Institutionen

  • Bioengineering Graduate Program, University of Kansas, Lawrence, Kansas 66045 United States.
  • Department of Medicine, Division of Allergy and Immunology, Washington University School of Medicine in St. Louis, St. Louis, Missouri 63110 United States.
  • Department of Biomedical Engineering, Washington University in St. Louis, St. Louis, Missouri 63130 United States.
  • Department of Infectious Diseases, Washington University School of Medicine in St. Louis, St. Louis, Missouri 63110 United States.
  • Department of Chemistry, Washington University in St. Louis, St. Louis, Missouri 63130, United States.

ORCID-Profile: Grant M Downes, Kyle D Apley, Cory J Berkland

Förderung

  • University of Kansas

Zitieren

APA

Downes, G. M., Griffith, A. S., Apley, K. D., Miller, M. J., Kendall, P. L., & Berkland, C. J. (2025). Engineered Nonhormonal, Cationic Proinsulin Variants Prolong Lymphatic Drainage. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c01189

Vancouver

Downes GM, Griffith AS, Apley KD, Miller MJ, Kendall PL, Berkland CJ. Engineered Nonhormonal, Cationic Proinsulin Variants Prolong Lymphatic Drainage. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.5c01189

BibTeX
@article{Downes2025,
  author = {Downes, Grant M and Griffith, Amber S and Apley, Kyle D and Miller, Mark J and Kendall, Peggy L and Berkland, Cory J},
  title = {Engineered Nonhormonal, Cationic Proinsulin Variants Prolong Lymphatic Drainage},
  journal = {Molecular Pharmaceutics},
  year = {2025},
  doi = {10.1021/acs.molpharmaceut.5c01189}
}
Kostenlos starten →